Hearing that imaging shows 'many small shadows scattered throughout the lungs,' followed by 'so surgery or a local procedure isn't possible and chemotherapy must continue,' can be devastating. It is natural to want each visible spot removed, and to feel frustrated at being told it cannot be done. This article does not claim which treatment is right; it aims to help you understand what doctors weigh when they separate local treatment from systemic treatment.
Metastasis is not only about whether it is present, but about how many there are, where they sit, and how widely they have spread. When there are only a few metastatic lesions in limited locations that can each be targeted, this is often called oligometastasis. In that situation, local treatments that focus on a narrow area — surgical removal (metastasectomy), burning or freezing (radiofrequency or cryoablation), or stereotactic body radiation (SBRT) — may be considered. In contrast, when many small lesions are scattered diffusely across the lungs, targeting them one by one becomes impractical.
The explanation that 'if there were just one or two larger ones a procedure might be possible, but many tiny scattered ones cannot be treated' can sound puzzling at first. Yet local treatment offers the most benefit when the target is clear and the number is small. When dozens of lesions are scattered, treating each with surgery or radiation would damage a great deal of healthy lung, and — more importantly — microscopic metastases too small to appear on scans are likely present as well. Here, systemic treatment that travels throughout the body — chemotherapy, targeted therapy, or immunotherapy — becomes the main tool for holding back both the scattered lesions and the seeds that cannot yet be seen.
So being told to 'keep going with chemotherapy' is not a sign of giving up; it usually means the team is choosing the most reasonable way to control disease that is spread widely. If systemic treatment shrinks the lesions so that only a few remain, whether to add local treatment can be discussed again. Treatment is not fixed once and for all; it is continually adjusted according to imaging and how the body is doing.
In the clinic you might ask: is the spread currently limited or widespread, what criteria would make local treatment worth considering, could shrinkage open the door to adding surgery or radiation, and if a clinical trial exists, what are its eligibility conditions and waiting times. If you are curious about hyperthermia or other complementary approaches, it is safest to ask your treating doctor first whether they can be combined safely with your current treatment.
This article is for general information and does not replace your own diagnosis or care. Please discuss any decisions fully with your treating medical team.